MARKET

ALMS

ALMS

Alumis Inc
NASDAQ
26.40
+1.37
+5.47%
After Hours: 26.29 -0.11 -0.42% 17:54 06/26 EDT
OPEN
25.01
PREV CLOSE
25.03
HIGH
26.50
LOW
24.71
VOLUME
6.16M
TURNOVER
--
52 WEEK HIGH
30.60
52 WEEK LOW
2.760
MARKET CAP
3.37B
P/E (TTM)
-13.7400
1D
5D
1M
3M
1Y
5Y
1D
Alumis management to meet with Cantor
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and Alnylam Pharma (ALNY)
TipRanks · 2d ago
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
Seeking Alpha · 2d ago
MapLight Therapeutics names Martin Babler, Troy Cox to board of directors
PUBT · 4d ago
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
TipRanks · 6d ago
Weekly Report: what happened at ALMS last week (0615-0619)?
Weekly Report · 6d ago
Weekly Report: what happened at ALMS last week (0608-0612)?
Weekly Report · 06/15 09:21
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch
NASDAQ · 06/15 02:02
More
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Webull offers Alumis Inc stock information, including NASDAQ: ALMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALMS stock methods without spending real money on the virtual paper trading platform.